

 NOVARTIS

# **Novartis in Switzerland**

Novartis in der Schweiz





## Contents

|   |    |
|---|----|
| Foreword  | 2  |
| We are Novartis                                   | 4  |
| Reimagine medicine together                       | 5  |
| Active worldwide, at home in Switzerland          | 6  |
| Our doors are open – experience Novartis          | 7  |
| Our commitment to patients and caregivers         | 9  |
| Our sites   | 10 |
| Novartis Switzerland in numbers                   | 12 |
| Our ways of working                               | 14 |
| Empowering the next generation                    | 16 |
| Our contribution to the Swiss economy and society | 18 |
| Local partnerships                                | 22 |
| Sponsoring and donations                          | 23 |
| Novartis in Society Integrated Report             | 24 |

# Foreword

Dear Reader,

2024 was an important year for Novartis as it marked our first full year as a pure-play innovative medicines company. We reached nearly 300 million patients with our innovative therapies — more than ever before — as we focused on our key therapeutic areas and technology platforms. We consistently delivered strong performance, significant research and development (R&D) achievements, and sustainable growth, and are well positioned to continuously increase value for all our stakeholders and the communities we serve.

Our strong presence in Switzerland remains key to these efforts. It is a central location for our R&D efforts with approximately 5 000 R&D experts located in Basel alone. In 2024, we invested a total of CHF 4.2 billion in R&D in Switzerland, comprising nearly half of our global R&D spending. Yet we can't drive progress alone. With around 120 active collaborations with Swiss academic institutions, including top-tier Swiss universities, we are shaping the research agenda together. Importantly, our medicines reached 1.36 million patients in Switzerland.


We recognize that there is more to do, including helping people navigate the human experience of disease and supporting the search for solutions to meet the changing needs of healthcare professionals and systems.

This is what drives us and what you can experience first-hand at the Novartis Pavillon. I cordially invite you to experience Novartis and join us on our journey to making healthcare better for everyone we serve.



**Lutz Hegemann**

President, Global Health and Swiss Country Affairs



An open Campus – new perspectives  
on and for Basel.

# We are Novartis

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives. In 2024, our medicines reached nearly 300 million patients around the world—more than ever before.

## We focus on core therapeutic areas with high unmet patient needs



Cardiovascular,  
renal, and metabolic



Neuroscience



Immunology



Oncology

## We focus on technology platforms that enable cutting-edge innovative therapies



Chemistry



xRNA



Biotherapeutics



Radioligand therapy



Gene and cell therapy

# Reimagine medicine together

To successfully reimagine medicine for decades to come,  
we need to partner with those who share our purpose.



This means listening to the voices of patients and caregivers so that we can create medicines and programs that meet their needs and allow them to live life on their terms.



Supporting healthcare professionals with solutions beyond breakthrough medicines.



Collaborating with stakeholders across the healthcare landscape so that we can have a greater impact on societal health.



**Find out more**  
about our strategy and our approach.  
(in German)

# Active worldwide, at home in Switzerland

We are strongly committed to our Swiss roots, which stretch back over 250 years. Our journey started in the dye and chemicals industries before evolving into a medicines company.

Novartis and our predecessor companies have played a significant role in the rise of the Basel area as a world-leading hub of life sciences, which has developed into a stable driver of the economy in Switzerland.

## Switzerland is a central location for our research and development efforts



Our headquarters in Basel and our other operations in Switzerland are home to 10 000 associates, with approximately 5 000 R&D colleagues located in Basel specifically.



In 2024, we invested CHF 4.2 billion into R&D in our home country, which account for nearly half of our global R&D expenditure.



In the research and preclinical space alone, we have around 120 active collaborations with scientific institutions in Switzerland, and we play a significant role in the vibrant Basel life sciences hub.

# Our doors are open – experience Novartis



## Novartis Campus Basel

The Novartis Campus in Basel serves as the global headquarters and provides a dynamic work environment for over 7 000 Novartis employees. It is distinguished by its thoughtful architectural design and spatial layout, purposefully crafted to cultivate an ideal environment for innovation.

**Experience the Campus with our audio tour:**  
Novartis Campus Walks



## Visit the Novartis Campus Basel

Opening hours: Monday to Friday, 7:00 to 19:00  
Guided tours can be booked via Basel Tourism  
[campus.novartis.com](https://campus.novartis.com)



## Novartis Pavillon

The Novartis Pavillon is home to the interactive multimedia exhibition “Wonders of Medicine.” Visit the exhibition to learn how the body works, how researchers develop new treatments, and what the future of healthcare might look like. It also offers a café, an innovative learning facility for school classes, as well as a variety of events, open to everyone.



## Visit the Novartis Pavillon

The Novartis Pavillon is open from Tuesday to Sunday.  
For more information and opening hours, visit our website:  
[pavillon.novartis.com](https://pavillon.novartis.com)





## Our commitment to patients and caregivers

Patients and caregivers know better than anyone what it is like to live with a serious disease. We listen. And we learn from people's experiences. We work together to create medicines that address the needs of people living with disease and achieve the results that matter to them.

Our work with patients and caregivers is built on four commitments:

Respecting and understanding the patient community perspective

Expanding access to our medicines

Conducting responsible clinical trials

Recognizing the importance of transparency and reporting

# Our sites

## 1 Basel (BS)

### 1.1 Novartis Campus Basel

- Company headquarters
- Head Office, International commercial unit
- Research and Development
- Operations and global functions
- More than 7 000 employees

### 1.2 Operations – manufacturing site

- Basel Drug Substance Supply (BDSS)
- Biotechnology site playing a key role in launching new biological entities
- Production, testing and release of clinical and commercial drug substances from mammalian cells and cell banks
- Approximately 180 employees

## 2 Schweizerhalle (BL)

### Operations – manufacturing site

- Chemical launch and production site
- Production of small-batch, innovative compounds and intermediate products for medicines
- State-of-the-art RNA oligonucleotide manufacturing facility for novel cardiovascular treatment
- Approximately 210 employees

## 3 Stein (AG)

### Operations – manufacturing site

- Launch and production of innovative medicines and treatments
- Center of Excellence for the production of sterile and solid dosage forms, as well as personalized cell and gene therapies
- Millions of tablets, capsules, syringes, vials, autoinjectors, and personalized medicines produced annually and shipped to over 140 countries worldwide
- Approximately 1 500 employees

## 4 Geneva (GE)

### Advanced Accelerator Applications, a Novartis Company

## 5 Fribourg (FR)

### Novartis Innovative Therapies AG

## 6 Rotkreuz (ZG)

### 6.1 Novartis Pharma Schweiz AG

- Swiss business unit
- Responsible for marketing around 75 prescription medicines in Switzerland
- Main therapeutic areas: Oncology, Cardiovascular, Immunology, and Neuroscience
- Covers areas such as medical consulting, quality assurance, marketing and sales as well as logistics, order processing, and the coordination of clinical trials.
- Approximately 220 employees

### 6.2 Novartis Innovative Therapies AG





# Novartis Switzerland in numbers

## Employees



## Employees' country of residence



## Research and development



## Sales

Novartis sales in Switzerland, including contract manufacturing activities



## Investment in property, plant, and equipment



## Current income taxes

Average value 2022 – 2024



Financial figures are based on 2024 IFRS Accounting Standard financial measures.



# Our ways of working

The greatest strength of Novartis is our people, whose diversity, energy and creativity are crucial to our success. We strive to unleash the power of our people, and we cultivate an inclusive company culture that is **inspired, curious, unbossed**, and of **integrity**.

To enable this culture, we are fully committed to ensuring the **health, safety, well-being, and work-life balance** of our people through a broad range of offers, which include:

- Flexible working options, including flextime and hybrid working models, part-time contracts, work-life balance models, and job sharing
- At least 18 weeks of paid parental leave for both birthing and non-birthing parents
- Childcare services and support for people who care for immediate family members or relatives
- Broad range of wellbeing programs targeting physical, mental, and social well-being activities
- Broad range of occupational health & safety programs, such as health services on site
- Stop the Work Authority in case people see or experience an unsafe situation, which will then be investigated and improved
- SpeakUp Office to raise concerns about potential misconduct

We aspire to build an inclusive culture where all of us can be our best and authentic selves.

- We have achieved our Equal Pay International Coalition (EPIC) pledge in 2023 and renewed it with three commitments to achieve by 2027
- We are recognized by the Swiss LGBTI Label as well as the Swiss Career Empowerment Label
- We are committed to ensuring inclusion for our people living with a visible or invisible disability, for example by removing behavioral and structural barriers
- We support our 16 Employee Resource Groups, which are grassroot communities with a shared set of interests, experiences, and perspectives

Furthermore, we empower our people to contribute on their terms to have an impact on society's biggest challenges and unmet needs. Through the Giving, Matching & Volunteering program, our employees support local communities and partner organizations across more than 60 causes and beneficiary areas.

# 100+

**Projects** supported by  
Novartis Volunteers in  
Switzerland in 2024



# Empowering the next generation

Talented, engaged, and responsible young individuals are our future. To empower the next generation, we offer a diverse range of development opportunities to those starting their careers.

## Novartis School<sup>Lab</sup>

At the Novartis School<sup>Lab</sup>, our mission is to ignite a passion for science among young individuals and offer them a glimpse into the professional world. With augmented reality and hands-on experiments, we offer a unique opportunity to explore the fascinating world of medicine.

More than 3 000 pupils from across Switzerland and the neighboring countries are visiting the School<sup>Lab</sup> each year.



## Vocational education and training

Do you want to join us on our journey to reimagine medicine to improve and extend peoples' lives? Start your journey with Novartis!

Each August, we welcome around 80 apprentices to our renowned apprenticeship program. With a focus on research and development, as well as production, our program equips trainees with valuable knowledge and skills across 11 different occupations.

## Students, graduates and early-in-career professionals

Are you ready to build a career with real impact? We offer a range of life-changing opportunities for students, graduates, and early-in-career professionals. Get energized by the scientific, technological and human brilliance all around you at Novartis. Join us in creating impact that helps to improve and extend millions of lives.

### We offer opportunities for

- Bachelor's and master's students
- Graduates
- Ph.D. students and postdocs



### Find out more

about our opportunities  
for the next generation.  
(in German)

# Our contribution to the Swiss economy and society

## Our social impact in Switzerland

1.36 million

patients reached in Switzerland

8 328

additional **healthy years**

Quality Adjusted Life Years: an international unit of measurement that indicates the years of life gained by patients in terms of improved health

## Our economic impact in Switzerland

CHF 22.7 billion

**direct contribution of Novartis to the Swiss Gross Domestic Product (GDP)**  
equals 3% of the total GDP















**One job** at Novartis secures **three additional jobs** at other companies in Switzerland<sup>1</sup>

<sup>1</sup> Novartis Social, Environmental, and Economic Impact Valuation (2024) according to the Value Balancing Alliance (VBA) methodology

Environmental sustainability targets

Human health and planetary health are intrinsically linked. We have set ourselves ambitious environmental targets to mitigate our impacts and become a net-zero company by 2040. Both our near- and long-term ambitions have been validated by the Science Based Targets initiative (SBTi).

In Switzerland, we are committed to supporting these targets in our operations. For example, by increasing our use of renewable energy and district heating, primarily sourced from wood and exhaust heat. We are also continuously improving the energy efficiency of our buildings.

|                | by 2025   | by 2030  | by 2040   |
|----------------|---|--|---|
| Climate        | <div><b>Carbon neutral</b><br/>in our own operations<br/>(Scope 1 and 2 from energy)</div> <div><b>Include environmental criteria</b><br/>in all supplier contracts</div>   | <div><b>Reduce Scope 1 and 2 GHG emissions</b> by 90 %<sup>1</sup></div> <div><b>Reduce Scope 3 GHG emissions</b> by 42 %<sup>1</sup></div>  | <div><b>Net-zero GHG emissions</b><br/>(90 % reduction)<br/>across our value chain<sup>1</sup><br/>(in accordance with the SBTi Corporate Net-Zero Standard)</div> |
| Nature – Waste | <div><b>Eliminate polyvinyl chloride (PVC)</b> in packaging<sup>2</sup></div> <div><b>Reduce the amount of waste</b> sent for disposal by 50 % from a 2016 base year</div>  | <div><b>Reduce the amount of waste</b> sent for disposal by 30 % from a 2022 base year</div>  |   |
| Nature – Water | <div><b>Reduce water consumption</b> in our own operations by half from a 2016 base year</div> <div><b>No water quality impacts</b> from manufacturing effluents<br/>(from own manufacturing sites and high-risk suppliers)</div> | <div><b>Water use reduction</b> for own and supplier sites based on water-stressed basins<sup>3</sup></div> <div><b>No water quality impacts</b> from manufacturing effluents<br/>(from own manufacturing sites, labs and all suppliers)</div> |   |

1 Absolute greenhouse gas (GHG) emissions from a 2022 base year

2 From Novartis owned and operated sites that are involved in secondary and tertiary packaging. This is supported by efforts to eliminate PVC from primary packaging where feasible.

3 Basin-specific targets will be established for sites in own operations and upstream suppliers.

For more details on our ESG targets, please refer to our Novartis in Society Integrated Report 2024.

## Local partnerships

We believe in the power of collaboration. From our partnerships with universities to our Giving, Matching & Volunteering partnerships with nonprofits, we work hand in hand with stakeholders across Switzerland to address healthcare challenges. Together, our collective impact is greater than anything we could achieve alone.

### **The Novartis Foundation: AI4HealthyCities Basel**

Studies show that only about 20% of our health outcomes are shaped by the healthcare we access, while about 80% are determined by genetics and the socio-economic and environmental conditions in which we live, grow, and age. AI4HealthyCities is a cardiovascular population health initiative designed and coordinated by the Novartis Foundation to progress understanding of what truly drives heart health, by using advanced analytics and AI on data from health- and health-influencing sectors. The Novartis Foundation's goal is to provide city authorities with tools to use the data-driven insights for better planning and resource allocation in health. Ultimately, the aim is to create a paradigm shift from healthcare to health, and transform the current reactive care systems into proactive, predictive, and preventive health systems that keep people healthy.

AI4HealthyCities is currently running in New York City, Singapore, and Helsinki. In 2024, the Novartis Foundation teamed up with the University Children's Hospital Basel (UKBB) to launch AI4HealthyCities in Basel.

## Sponsoring and donations

Novartis Donations provides support to a range of initiatives and projects in the areas of humanitarian aid, emergency assistance during disasters, and engagement in social affairs.

Novartis extends its support to culture, education, and sports through sponsorship commitments. This support is directed toward activities that are either relevant to our purpose as a healthcare company or situated in close geographic proximity to Novartis sites.

FC Basel 1893 women's team;  
picture: Samira Sutter



# Novartis in Society Integrated Report

Read more about our performance against our environmental, social, and governance (ESG) priorities in the Novartis in Society Integrated Report 2024, covering topics such as innovation, access to medicines, ethical culture, and environmental impact.



## **Imprint**

Novartis International AG  
4002 Basel, Switzerland

## **General inquiries**







+41 61 324 11 11  
[novartis.ch](https://www.novartis.ch)

## **medPortal**

Information and service platform  
for healthcare professionals.  
Registration necessary.  
[medportal.ch](https://www.medportal.ch)





- 
-  NovartisCH
  -  Novartis\_CH
  -  Novartis\_CH
  -  Novartis\_CH
  -  Novartis Pharma Schweiz

**Cover picture**

The zero-energy media façade of the Novartis Pavillon displays science-inspired digital art. In this picture: Esther Hunziker, "Inside," 2022.